Imaging in dementia with lewy bodies: A review

Nuclear Medicine Communications

Volumn 28, Issue 7, 2007, Pages 511-519

  Kemp, Paul M ^a   Holmes, Clive ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Dementia with Lewy bodies; FP CIT; HMPAO; Lewy body dementia; PET; SPECT

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; RADIOLIGAND;

ALZHEIMER DISEASE; BRAIN PERFUSION; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; EPISODIC MEMORY; HUMAN; LEWY BODY; NEOCORTEX; OCCIPITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; HUMANS; LEWY BODY DISEASE; RADIOISOTOPES; RECEPTORS, DOPAMINE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 34249819658     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3281e20a12     Document Type: Review

References (63)

1. McKeith IG. Dementia with Lewy bodies: a clinical review. In: Burn D, O’Brien JT, Dementia, 3rd edition. London: Hodder Arnold; 2005. pp. 603-614.
2. Mega MS, Masterman DL, Benson F, Vinters HV, Tomiyasu U, Craig AH, et al. Dementia with Lewy bodies: reliability and validity of clinical and pathological criteria. Neurology 1996; 47:1403-1409.
3. Luis CA, Barker WW, Gajara K, Harwood D, Petersen R, Kashuba A, et al. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy verified sample. Int J Geriatr Psychiatry 1999; 14:526-533.
4. Holmes C, Cairns N, Lantos P, Mann A. Validity of current criteria for Alzheimer’s disease, vascular dementia and dementia with Lewy bodies. Br J Psychiat 1999; 174:45-50.
5. McKeith IG, Ballard CG, Perry RH, Ince PG, O’Brien JT, Neill D, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000; 54:1050-1058.
6. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson’s disease [Review]. Arch Neurol 1999; 56:33-39.
7. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125:391-403.
8. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson’s disease neuropathology. Arch Neurol 2002; 59:102-112.
9. Emre M. Dementia associated with Parkinson’s disease [Review]. Lancet Neurology 2003; 2:229-237.
10. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies [Review]. Lancet Neurology 2004; 3:19-28.
11. Cummings JL. Intellectual impairment in Parkinson’s disease: Clinical, pathologic and biochemical correlates. J Geriat Psychol Neurol 1998; I:24-36.
12. McKeith IG, O’Brien J. Dementia with Lewy bodies. Aust NZ J Psychiat 1999; 33:800-808.
13. Varma AR, Adams W, Lloyd JJ. Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer’s disease, fronto-temporal dementia and vascular dementia. Acta Neurol Scand 2002; 105:261-269.
14. O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognition impairment [Review]. Lancet Neurology 2003; 2:89-98.
15. Barber R, Scheltens P, Gholkar A, Ballard C, McKeith I, Ince P, et al. White matter lesions on MRI in dementia with Lewy bodies, Alzheimer’s disease, vascular dementia and normal ageing. J Neurol Neurosurg Psychiat 1999; 67:66-72.
16. Barber R, Gholkar A, Sheltens P, Ballard C, McKeith IG, O’Brien JT, et al. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999; 52:1153-1158.
17. Pasquier F, Hamon M, Lebert F, Petit H. Medial temporal lobe atrophy in memory disorders. J Neurol 1997; 244:175-181.
18. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s disease; rostro-caudal distribution. Brain 1999; 122:1449-1468.
19. 18F-Fluorodopa PET study of striatal dopaminergic uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000; 55:1575-1576.
20. Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiat 2002; 73:134-140.
21. Ceravolo R, Volterrani D, Gambaccini G, Rossi C, Logi C, Manca G, et al. Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer’s disease. Neurol Sci 2003; 24:162-163.
22. O’Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualised with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004; 61:919-925.
23. 123I-FP-CIT SPECT in dementia with Lewy bodies; a phase III multi-centre, prospective study. Lancet Neurology 2007; 6:305-313.
24. Costa DC, Walker Z, Walker RW, Fontes FR. Dementia with Lewy bodies versus Alzheimer’s disease: Role of dopamine transporter imaging. Mov Disord 2003; 18:S34-S38.
25. Walker Z, Costa DC, Walker RH, et al. Comparison of FP-CIT imaging and autopsy diagnosis of DLB [Abstract]. J Neurol Sci 2006; 248:303
26. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, et al. The Lewy body variant of Alzheimer’s disease: A clinical and pathologic entity. Neurology 1990; 40:1-8.
27. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60:1586-1590.
28. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 2005; 65:1863-1872.
29. Walker Z, Costa DC, Janssen AG, Walker RWH, Livingstone G, Katona CLE. Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single photon emission tomography. Eur J Nucl Med 1997; 24:609-614.
30. 123I-IBZM SPECT for the diagnosis of Parkinsonian syndromes; study on 72 patients. J Neural Transmission 2005; 112:677-692.
31. 123I-IBZM-SPECT. J Neurol Neurosurg Psychiat 1994; 57:1047-1056.
32. Hierholzer J, Cordes M, Venz S, Schelosky L, Harisch C, Richter W, et al. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J Nucl Med 1998; 39:954-960.
33. Colloby SJ, Fenwick JD, Williams ED, Paling SM, Lobotesis K, Ballard C, et al. A comparison of Tc-99m HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s disease using statistical parametric mapping. Eur J Nucl Med 2002; 29:615-622.
34. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001; 56:643-649.
35. 99mTc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med 2002; 29:1342-1348.
36. Hanyu H, Schimizu S, Hirao K, Kanataka H, Sakurai H, Iwamoto T, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using Mini-Mental State Examination and brain perfusion SPECT. J Neurol Sci 2006; 250:97-102.
37. Mito Y, Yoshida K, Yabe L, Makino K, Hirotani M, Tashiro K, et al. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson’s disease with and without dementia, and Alzheimer’s disease. Clin Neurol Neurosurg 2005; 107:396-403.
38. 123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2006; 33:248-253.
39. Ishii K, Yamaji S, Kitagaki H, Imamura T, Hirono N, Mori E. Regional cerebral blood flow differences between dementia with Lewy bodies and AD. Neurology 1999; 53:413-416.
40. Shimizu S, Hanyu H, Kanetaka H, Iwamoto T, Koizumi K, Abe K. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using brain SPECT. Dement Geriatr Cogn Disord 2005; 20:25-30.
41. Defebvre LJP, Leduc V, Duhamel A, Lecouffe P, Pasquier F, Lamy-Lhullier C, et al. Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer’s disease and idiopathic Parkinson’s disease. J Nucl Med 1999; 40:956-962.
42. Steinling M, Defebvre L, Duhamel A, Lecouffe P, Lavenu I, Pasquier F, et al. Is there a typical pattern of brain SPECT imaging in Alzheimer’s disease? Dement Geriatr Cogn Disord 2001; 12:371-378.
43. Kemp PM, Hoffmann A, Tossici-Bolt L, Fleming JS, Holmes C. Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nucl Med Commun 2007; 28:451-456.
44. Ishii K, Imamwa T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology 1998; 51:125-130.
45. Minoshima S, Foster NZ, Sima AA. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001; 50:358-365.
46. Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S, et al. Glucose hypometabolism and Neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000; 162:247-256.
47. Imamura T, Ishii K, Sasaki M, Kitagaki H, Yamaji S, Hirono N, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease: a comparative study using positron emission tomography. Neurosci Lett 1997; 235:49-52.
48. Salmon E, Collette F, Degueldre C, Lemaire C, Franck G. Voxel-based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer’s disease. Human Brain Mapping 2000; 10:39-48.
49. Bradley KM, O’Sullivan VT, Soper ND, Nagy Z, King EM, Smith AD, et al. Cerebral perfusion SPECT correlated with Braak pathological stage in Alzheimer’s disease. Brain 2002; 125:1772-1781.
50. Huang C, Wahlund LO, Svensson L, Winblad B, Julin P. Cingulate cortex hypoperfusion predicts Alzheimer’s disease in mild cognitive impairment. BMC Neurol 2002; 2:9-14.
51. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reductions in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997; 42:85-94.
52. 99mTc-HMPAO SPECT in mild Alzheimer’s and Lewy body dementia. Nucl Med Commun 2005; 26:1099-1106.
53. Ishii K, Sakamoto S, Sasaki M, Kitagaki H, Yamaji S, Hashimoto M, et al. Cerebral glucose metabolism in patients with fronto-temporal dementia. J Nucl Med 1998; 39:1875-1878.
54. McKeith IG, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurology 2004; 3:19-28.
55. 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer’s disease. J Neurol Neurosurg Psychiat 2001; 70:781-783.
56. 123I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s type and dementia with Lewy bodies. J Neurol Neurosurg Psychiat 2001; 71:583-588.
57. 123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer’s disease and dementia with Lewy bodies. Int Med 2003; 42:686-690.
58. Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155:60-67.
59. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Autonom Res 2001; 11:351-355.
60. McKeith IG, Fairbairn AF, Perry RH, Thompson P, Perry E. Neuroleptic sensitivity of patients with senile dementia of the Lewy body type. BMJ 1992; 305:673-678.
61. Tiraboschi P, Mansen LA, Alford M, Sabbagh MN, Schoos B, Nasliah E, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000; 54:407-411.
62. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, et al. Better cognitive and psychological response to donepezil in patients with prospectively diagnosed as dementia with Lewy bodies; a preliminary study. Int J Geriatr Psychiat 2000; 15:794-802.
63. National Institute for Health and Clinical Excellence. Dementia: Supporting People with Dementia and their Carers in Health and Social Care. NICE Clinical Guideline Number 42. London: National Institute for Health and Clinical Excellence; 2006.